Wedbush Lifts United Therapeutics' Price Target to $307 From $305 After 'Strong' Q2 Results, Keeps Outperform Rating
Wedbush Lifts United Therapeutics' Price Target to $307 From $305 After 'Strong' Q2 Results, Keeps Outperform Rating
在第二季度业绩 “强劲” 之后，Wedbush将United Therapeutics的目标股价从305美元上调至307美元，保持表现跑赢大盘的评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册